News & Updates
Filter by Specialty:
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
27 Oct 2021
Chronic constipation not a risk factor for later colorectal cancer
Individuals with chronic constipation do not seem to be at increased risk of developing subsequent colorectal cancer as compared with their peers who do not have the gastrointestinal condition, as reported in a study.
Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021
High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D
Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.
High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D
27 Oct 2021
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
26 Oct 2021
Atrophic gastritis, PPI use amplify EC risk in immunocompetent patients
In immunocompetent patients admitted at a community hospital, comorbidities such as advanced gastric cancer and atrophic gastritis (AG), as well as treatment with proton pump inhibitors (PPI), seem to aggravate the risk of developing oesophageal candidiasis (EC), a recent study has found.
Atrophic gastritis, PPI use amplify EC risk in immunocompetent patients
26 Oct 2021
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.